[go: up one dir, main page]

PE20090907A1 - Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente - Google Patents

Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente

Info

Publication number
PE20090907A1
PE20090907A1 PE2008001219A PE2008001219A PE20090907A1 PE 20090907 A1 PE20090907 A1 PE 20090907A1 PE 2008001219 A PE2008001219 A PE 2008001219A PE 2008001219 A PE2008001219 A PE 2008001219A PE 20090907 A1 PE20090907 A1 PE 20090907A1
Authority
PE
Peru
Prior art keywords
thotrope
excipient
lactose
salmeterol
well
Prior art date
Application number
PE2008001219A
Other languages
English (en)
Inventor
Michael Waltz
Stephanie Ossadnik
Michael Trunk
Christoph Kreher
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20090907A1 publication Critical patent/PE20090907A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A61M15/0026—Hinged caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA FORMULACION DE POLVOS INHALABLES QUE COMPRENDE XINAFOATO DE SALMETEROL EN UNA DOSIS DE 12,5 µg A 50 µg, UNA SAL DE TIOTROPIO TAL COMO CLORURO, BROMURO, YODURO, METANOSULFONATO O PARA-TOLUENSULFONATO EN UNA DOSIS DE 3,8 µg A 15 µg, PREFERENTEMENTE, BROMURO DE TIOTROPIO MONOHIDRATADO, Y UN EXCIPIENTE TAL COMO LACTOSA. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES DE LAS VIAS RESPIRATORIAS, ESPECIALMENTE, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
PE2008001219A 2007-07-21 2008-07-17 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente PE20090907A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007034157 2007-07-21
US5193308P 2008-05-09 2008-05-09

Publications (1)

Publication Number Publication Date
PE20090907A1 true PE20090907A1 (es) 2009-08-05

Family

ID=39869109

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001219A PE20090907A1 (es) 2007-07-21 2008-07-17 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente

Country Status (9)

Country Link
US (1) US20100189780A1 (es)
EP (1) EP2182933B1 (es)
JP (1) JP2011509919A (es)
AR (1) AR067639A1 (es)
CA (1) CA2694479C (es)
PE (1) PE20090907A1 (es)
TW (1) TW200909004A (es)
UY (1) UY31235A1 (es)
WO (1) WO2009013244A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100638936B1 (ko) * 2005-03-31 2006-10-25 엘지전자 주식회사 건조기의 캐비닛 구조
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
DK2277799T3 (da) * 2009-07-23 2012-05-21 Airsec Sas Hydreret fugtighedsbekæmpelsesstof og fremgangsmåde til fremstilling deraf
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
MD4117C1 (ro) * 2010-07-30 2012-02-29 Институт Химии Академии Наук Молдовы Pudră cu capacitate hemostatică şi regenerativă (variante) şi procedeu de obţinere a acesteia
WO2012028663A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
US20130156828A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ITMI20120092A1 (it) * 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
US8545878B1 (en) 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
CN105142673B8 (zh) 2012-12-18 2018-02-16 阿尔米雷尔有限公司 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
EA201790833A1 (ru) * 2014-10-16 2017-09-29 Тева Брэндид Фармасьютикал Продактс Ар Энд Ди, Инк. Сухой порошкоообразный состав
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
CA173518S (en) 2016-02-08 2017-09-01 Nicoventures Holdings Ltd Cartridge for an electronic cigarette
GB201605105D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Vapour provision apparatus
GB201605100D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Vapour provision system
GB201605102D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Mechanical connector for electronic vapour provision system
GB201605101D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Electronic vapour provision system
EP3487776A1 (en) 2016-07-22 2019-05-29 Nicoventures Holdings Limited Case for a vapour provision device
EP3910324A1 (en) * 2018-08-07 2021-11-17 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
PL244452B1 (pl) * 2020-08-24 2024-01-29 Pulinno Spolka Z Ograniczona Odpowiedzialnoscia Inhalator kapsułkowy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002822L (sv) * 2000-08-04 2002-01-29 Microdrug Ag Elektropulver
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
JP3691459B2 (ja) * 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
UA83813C2 (ru) * 2002-12-20 2008-08-26 Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler

Also Published As

Publication number Publication date
CA2694479C (en) 2016-09-13
TW200909004A (en) 2009-03-01
US20100189780A1 (en) 2010-07-29
AR067639A1 (es) 2009-10-21
CA2694479A1 (en) 2009-01-29
EP2182933A1 (de) 2010-05-12
EP2182933B1 (de) 2016-09-07
WO2009013244A1 (de) 2009-01-29
UY31235A1 (es) 2009-03-02
JP2011509919A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
PE20090907A1 (es) Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
UA101653C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
EA201401354A1 (ru) Новая дозированная форма и препарат, содержащий абедитерол
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
UA100777C2 (ru) Вдыхаемые частички, содержащие тиотропий
UA98136C2 (ru) Применение аклидиния для лечения респираторных заболеваний
JP2007520506A5 (es)
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
HRP20050570A2 (en) Powdered medicament for inhalation comprising a tiotropium salt and salmetrol xinafoate
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
MX357556B (es) Composiciones acuosas que comprenden arbekacina.
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
Jones et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN
US20130123364A1 (en) N6-(1-iminoethyl)-l-lysine for regeneration of alveoli in lungs
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina
Hilberg et al. Inhaled voriconazole-an efficient treatment against invasive aspergillosis
Seed et al. Another plausible explanation for mist inhaler’s toxicity
Lu et al. Assessment of Efficiency of Nebulized Ceftazidime and Amikacine in Patients with Pneumonia Caused by Pseudomonas aeruginosa.
ACETYLCYSTEINE DRUG: ACETYLCYSTEINE
Cereda et al. Transient Receptor Potential Vanilloid Antagonism Alleviates The Propagation Of Lung Injury
RU2007120231A (ru) Способ лечения хронических неспецифических заболеваний легких с помощью ингаляций сухого аэрозоля натрия хлорида, импрегнированного серебром
Make et al. D44 COPD: TREATMENT FROM BRONCHODILATORS TO OTHER PHARMACOLOGICAL INTERVENTIONS: Lung Function And Safety Of Aclidinium Bromide/formoterol Fumarate Fixed-Dose Combination: Results Of A 1-Year Trial In Patients With COPD
Wilder et al. Murine Models Of Self-Limiting And Progressive Radiation-Induced Lung Damage

Legal Events

Date Code Title Description
FD Application declared void or lapsed